GSK lifted profit expectations for the year after the pharma group's sales were boosted by bumper demand for HIV and cancer ...
GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...
Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or even know they're an option. It's called pre-exposure prophylaxis, or ...
A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more? CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...
Doctors at DAP Health have begun administering a new twice-a-year injectable HIV prevention medication, which was approved by the Food and Drug Administration in June. Gilead's drug lenacapavir ...
A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...
A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach. A newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback